We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: BCMA
MedXY News
EnglishTag

BCMA

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis
Hematology-Oncologyrelapsed/refractoryBCMA

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

By MedXY|Sep 13, 2026

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and saf

CT0590: A Triple-Knockout Allogeneic BCMA CAR T Therapy Advances Treatment in Multiple Myeloma and Plasma Cell Leukemia
Hematology-Oncology
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
BCMA
multiple myeloma

CT0590: A Triple-Knockout Allogeneic BCMA CAR T Therapy Advances Treatment in Multiple Myeloma and Plasma Cell Leukemia

By MedXY|Sep 11, 2026

CT0590, a novel allogeneic BCMA CAR T-cell therapy armored with NKG2A to resist host NK cell attacks, demonstrates promising safety and efficacy in relapsed/refractory multiple myeloma and plasma cell leukemia, addressing key transplant rej

Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease
Hematology-OncologyGPRC5DBCMA

Dual-Targeted Anti-BCMA/GPRC5D CAR T-Cell Therapy Shows Promise in Relapsed/Refractory Multiple Myeloma with Extraosseous Extramedullary Disease

By MedXY|Aug 20, 2026

Bispecific anti-BCMA/GPRC5D CAR T cells demonstrate high response rates and manageable safety in patients with relapsed/refractory multiple myeloma complicated by extraosseous extramedullary disease, a group with historically poor outcomes.

Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma
Hematology-OncologyBCMAmultiple myeloma

Pavurutamab, a BCMA-Targeting Bispecific T-Cell Engager: Promising Phase 1/1b Results in Triple-Class Relapsed/Refractory Multiple Myeloma

By MedXY|Jul 13, 2026

Pavurutamab demonstrates manageable safety and encouraging efficacy in heavily pretreated relapsed/refractory multiple myeloma, showing an overall response rate of 46.5% and median progression-free survival of 16.8 months at the recommended

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion
Hematology-OncologyBCMABispecific Antibodies

Beyond the Plasma Cell: Why Anti-BCMA Bispecifics Increase Infection Risk via Early B-Cell Depletion

By MedXY|Mar 13, 2026

A landmark study reveals that anti-BCMA bispecific antibodies, unlike anti-GPRC5D, deplete B-cell precursors from the small pre-B stage onward, explaining the significantly higher infection rates observed in multiple myeloma patients.

AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data
Hematology-OncologyBCMACAR-T

AZD0120 (GC012F) Dual-Target BCMA/CD19 CAR‑T Shows Promising Early Activity and Favorable Safety in RRMM: Interpreting ASH 2025 Ib Data

By MedXY|Dec 9, 2025

Early Ib results from AstraZeneca’s AZD0120 (GC012F), a FasTCAR-derived BCMA/CD19 dual-target CAR‑T, reported 100% ORR in evaluable RRMM patients with low-grade CRS and no ICANS. Findings are encouraging but limited by small numbers and sho

Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma
Hematology-OncologyBCMAGPRC5D

Ramantamig (JNJ-79635322): A Trispecific T‑Cell Engager Targeting BCMA and GPRC5D Shows Potent Preclinical Activity in Multiple Myeloma

By MedXY|Nov 17, 2025

Ramantamig (JNJ-79635322), a trispecific antibody that engages BCMA, GPRC5D and CD3, demonstrates sub-nanomolar cytotoxicity, ex vivo depletion of patient plasma cells, and antitumor activity in xenograft models—supporting ongoing phase 1 t

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach
Hematology-OncologyBCMACAR‑T

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach

By MedXY|Nov 12, 2025

In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and pla

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results
Hematology-OncologyBCMAbelantamab mafodotin

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results

By MedXY|Nov 4, 2025

The DREAMM-7 phase 3 trial shows that belantamab mafodotin combined with bortezomib and dexamethasone produces early, sustained, and statistically significant overall survival and deep, durable responses versus daratumumab-based therapy in

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming
Hematology-OncologyBCMACAR T-cell therapy

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY|Oct 14, 2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune ev

Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety
Hematology-OncologyBCMACAR T-cell therapy

Advancing Treatment in Relapsed/Refractory Plasma Cell Myeloma: Dual-Nanobody BCMA CAR T-Cell Therapy Shows Promising Efficacy and Safety

By MedXY|Oct 8, 2025

Nanobody-based dual-targeting BCMA CAR T-cell therapy demonstrates high response rates and manageable safety in relapsed/refractory plasma cell myeloma, including high-risk subgroups.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities